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MULTI-MODALITY PLASMA-BASED DETECTION OF MINIMAL RESIDUAL 
DISEASE IN TRIPLE-NEGATIVE BREAST CANCER 
Triple-negative breast cancers (TNBCs) are pathologically defined by the absence 
of estrogen, progesterone, and HER2 receptors. Compared to other breast cancers, TNBC 
has a relatively high mortality. In addition, TNBC patients are more likely to relapse in 
the first few years after treatment, and experiencing a shorter median time from 
recurrence to death. Detecting the presence of tumor in patients who are technically 
“disease-free” after neoadjuvant chemotherapy and surgery as early as possible might be 
able to predict recurrence of patients, and then provide timely intervention for additional 
therapy. To this end, I applied the analysis of “liquid biopsies” for early detection of 
minimal residual disease (MRD) on early-stage TNBC patients using next-generation 
sequencing. For the first part of this study, I focused on detecting circulating tumor DNA 
(ctDNA) from TNBC patients after neoadjuvant chemotherapy and surgery. First, patient-
specific somatic mutations were identified by sequencing primary tumors. From these 
data, 82% of the patients had at least one TP53 mutation, followed by 16% of the patients 
having at least one PIK3CA mutation. Next, I sequenced matched plasma samples 
collected after surgery to identify ctDNA with the same mutations. I observed that by 
detecting corresponding ctDNA I was able to predict rapid recurrence, but not distant 
recurrence. To increase the sensitivity of MRD detection, in the second part I developed a 
strategy to co-detect ctDNA along with circulating tumor RNA (ctRNA). An advantage 
of ctRNA is its active release into the circulation from living cancer cells. Preliminary 
data showed that more mutant molecules were identified after incorporating ctRNA with 
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ctDNA detection in a metastatic breast cancer setting. A validation study in early-stage 
TNBC is in progress. In summary, my study suggests that co-detection of ctDNA and 
ctRNA could be a potential solution for the early detection of disease recurrence. 
Milan Radovich, PhD, Chair 
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Chapter 1: Introduction 
 
1.1 Triple-negative breast cancer 
 
1.1.1 Clinical features and current standard of care of triple-negative breast cancer 
Breast cancer is the most prevalent cancer type among women in the world and in 
the United States. In 2018, there were more than 260,000 estimated new cases of breast 
cancer and more than 40,000 are estimated to die from the disease [1]. Among those 
cases, about 15% of cases are categorized as triple-negative breast cancer (TNBC). 
TNBC is defined by the lack of estrogen (ER), progesterone (PR), and human epidermal 
growth factor receptor 2 (HER2) over-expression (Figure 1) [2-6]. While TNBC 
comprises a minority of breast cancer cases, it results in a disproportionally higher rate of 
mortality (Figure 2) [7]. Compared to ER- and HER2-positive disease, TNBCs have a 
higher incidence of visceral metastasis, a higher chance of recurrence within the first 3 
years after chemotherapy and surgery, and a shorter overall survival (OS) after the onset 
of metastatic disease (Figure 3) [8, 9]. Compared to other subtypes of breast cancer, 
TNBCs tends to occur more often in women who are younger, of African-
American/African descent, or Hispanic ethnicity. In addition, women who are carriers of 
pathologic germline mutations in BRCA1 have a higher risk of developing TNBC [10]. 
Histologically, TNBCs can be categorized into several subtypes. Around 95% of 
TNBCs are classified as invasive ductal carcinoma, followed by 1-2% as invasive lobular 
carcinoma, less than 1% as spindle-cell metaplastic carcinoma, adenoid cystic carcinoma, 
and other rare histologies. Among those, adenoid cystic carcinoma, adenosquamous 
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carcinoma and fibromatosis-like spindle-cell metaplastic carcinomas are less aggressive 
and usually relapse locally [11].  
Unlike ER/PR positive or HER-2 positive breast cancers, who have endocrine 
therapy or HER-2 targeted therapy, patients with TNBC typically receive chemotherapy 
alone. The current standard of care for TNBC patients incorporates the use of various 
chemotherapy including anthracyclines (e.g. doxorubicin), taxanes (e.g. paclitaxel and 
docetaxel), and cyclophosphamide in the adjuvant and neoadjuvant settings. More 
recently, PARP inhibition has been FDA approved for HER2-negative breast cancers in 
patients that carry a deleterious BRCA1/2 germline mutation [12, 13]. And in March 
2019, the FDA approved the first immunotherapy for metastatic TNBC, atezolizumab, for 
patients whose tumors have a PD-L1 IHC staining of 1% or greater based on results from 
the IMpassion130 trial [14]. 
A significant proportion of patients with early-stage TNBC are treated with 
neoadjuvant chemotherapy. Based on response of patients to neoadjuvant therapy, a stark 
dichotomy exists in outcome. Approximately a third of patients will achieve a pathologic 
complete response (pCR) and go on to have a favorable overall survival (OS) outcome 
(94% at 3 years). On the contrast, two-thirds of patients have residual disease after 
neoadjuvant chemotherapy and are at a high risk of relapse leading to an inferior OS 






Figure 1: The pathological patterns of different subtypes of breast cancer. H&E staining 
shows cancer histology. The positive or negative status for hormone receptors ER, PR 
and HER2 categorizes breast cancers into four major clinical subtypes. Adapted from 







Figure 2: Rates of breast-specific survival in triple-negative and other breast cancers. 













Figure 3: The hazard rates of distant recurrence of triple-negative breast cancer and non-
triple-negative breast cancer. Triple-negative breast cancer is more likely to relapse in the 










1.1.2 Molecular characteristics of TNBC 
TNBCs are a collection of breast tumors that are negative for ER, PR and HER-2 
by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). 
Although clinical guidance for breast cancer patients still depend mainly on those three 
markers, advancements in ‘omics’ technologies over the past two decades have allowed 
us to have a better understanding of this disease on the molecular level, and perhaps to 
discover molecular patterns that would have clinical benefits for subgroups of patients. In 
2000, Perou et al. had utilized cDNA microarrays representing 8102 human genes to 
characterize gene expression patterns of human breast tumors [16]. In this study, breast 
cancers were classified as HER-2, Luminal A and B, normal-like, and basal-like (Figure 
4) [17, 18]. Further studies showed an association between basal-like breast cancer and 
germline BRCA1 mutations [19-21].  
Basal-like breast cancer is often referred to as TNBC since the majority of the 
basal-like tumors are usually negative for ER, PR and HER-2. However, not all TNBC 
tumors are basal-like breast cancer: around 50% to 75% of basal-like breast cancers are 
classified as TNBC [22]. Conversely, basal-like breast cancer represents the most 
prevalent subtype of TNBC (55% to 81%) (Figure 5) [23, 24].  
BRCA1 mutations are found in less than 5% in sporadic tumors [25]. However, 
women with the presence of germline mutation in BRCA1 will have higher risk to 
develop breast cancer lifetime [26]. There is a strong association existing between 
BRCA1 mutations, TNBC and basal-like phenotype. More than 75% of breast cancer 
tumors carrying BRCA1 mutations have a basal-like phenotype, TNBC phenotype, or 






Figure 4: Example of stratification of breast cancer using gene expression patterns for hierarchical cluster analysis. Breast tumors are 






Figure 5: Comparison of intrinsic molecular subtypes and pathological subtypes among 
TNBC tumors and basal-like breast cancer tumor. The most frequent intrinsic subtype of 
TNBC is basal-like; the most frequent pathological subtype of basal-like breast cancer is 





1.2 Liquid biopsy on cancer detection and therapeutic monitoring 
 
1.2.1 Sources of liquid biopsy for cancer detection 
Tissue biopsy samples are commonly used in the clinic to diagnose, histologically 
characterize, and determine the hormonal status of breast tumors. Further, the tumor-
derived material from biopsy can potentially provide pathological and molecular 
information to guide the selection of therapy. However, there are still limitations of 
utilizing tissue biopsy. Some lesions are not safe or feasible to access. In addition, it is 
also difficult to perform serial sampling on tissue samples. Moreover, tissue biopsy 
samples cannot completely represent the whole tumor bulk and may not capture the 
heterogeneity for a given patient’s disease.  
An emerging method for non-invasive cancer detection is the analysis of tumor-
derived material from body fluids, such as blood, also known as “liquid biopsies”. 
Compared to tissue biopsy, liquid biopsy is less invasive and more feasible for patients. 
Liquid biopsy can capture the mutational heterogeneity of a patient’s disease, in 
particular for those with multi-focal metastatic disease, where cell-free DNA from the 
various metastases is shed into the circulation and analyzed. Furthermore, by serial 
sampling, liquid biopsy can be utilized to monitor treatment response, to potentially 
discover mutations which will lead to therapeutic resistance [29] (Figure 6), and also to 
detect minimal residual disease (MRD) prior to clinical recurrence.  
Although the majority of the studies on liquid biopsy have focused on blood or 
plasma, other bodily fluids have been selected according to tumor types, such as urine for 
bladder cancer and prostate cancer, saliva for head and neck cancer, and cerebrospinal 
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fluid (CSF) for brain cancer and neurodegenerative disease [30] (Figure 7). Other sources 
of non-invasive biopsy have also been used to detect the presence of tumor, including: 






Figure 6: Liquid biopsy can be used to monitor the response of treatment. Serial sampling 
of plasma to detect different mutations over times and help guide the selection of 
treatment: continue the same therapy or select a new therapy according to the mutations 


















Figure 7: Sources of liquid biopsy. Tumor-derived material can be found in a variety of 
bodily fluids. Those include exosomes, ctDNA, and circulating tumor cells (CTC). 




1.2.2 Overview of circulating biomarkers and their applications in breast cancer 
Circulating biomarkers have been increasingly utilized to reveal the information 
of diseases at the DNA level for genomic aberration, including mutations and copy 
number variations; at the epigenome level [31] to detect methylation patterns, and at the 
transcriptome level [32] for gene expression and fusion detection. Circulating biomarkers 
have also been used to generate information about the proteome [33-35] and the 
metabolome [36]. 
Protein biomarkers such as CA 15-3, CA-125, and prostate-specific antigen (PSA) 
have been applied as tumor protein biomarkers for breast cancer, ovarian cancer, and 
prostate cancer, respectively, for decades. However, the sensitivity and specificity of 
these biomarkers are moderate, especially in early-stage patients [37-40].  
In recent years, the most common and well-studied circulating biomarker is called 
cell-free DNA (cfDNA). cfDNA was first discovered in 1948 by Mandel and Metais [41]. 
In 1977, Leon et al. found that there were higher concentrations of cfDNA in cancer 
patients than in healthy individuals [42]. Subsequently in the 1990s, a few groups 
identified tumor-specific mutations and microsatellite alterations in cfDNA of cancer 
patients [43-46]. cfDNA has also been applied in noninvasive prenatal test (NIPT) since 
1997 when Lo et al. first identified fetal cfDNA in pregnant women [47].  
cfDNA is the DNA released into circulation from apoptosis or necrosis of tissue, 
including tumor tissue or circulating tumor cells (CTCs). cfDNA from tumors is called 
circulating tumor DNA (ctDNA). It has been demonstrated that ctDNA can be detected in 
many types of cancer, including: breast [48-52], prostate [53], gastric [54], and others 
[55]. ctDNA can be defined as any alterations on the sequence, such as tumor-specific 
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genomic mutations, copy number variations, and rearrangement; or any epigenetic 
aberrations, such as methylation.  
Another widely studied circulating biomarker are circulating tumor cells (CTC). 
CTCs are cells shed into circulation from primary or metastatic tumors. Tools to isolate 
CTCs from blood apply the strategy of positive selection, negative selection, or both. 
CellSearch is the first FDA-approved CTC detector, which positively enriches CTCs that 
express the epithelial cell adhesion molecule (EpCAM) but do not express the blood-cell 
marker CD45. CellSearch is suitable for enumeration of CTC, but it cannot separate 
single CTCs for downstream molecular experiments. In addition, it has been shown that 
not every CTC expresses EpCAM. Other groups have tried to incorporate different 
markers into the new systems to enhance CTC enrichment and isolate individual CTCs, 
such as DEPArray. These single CTCs can then be prepared for single-cell whole genome 
sequencing (WGS) or whole transcriptome sequencing (WTS).  
 In 2013, Dawson et al. published an analysis to compare the sensitivity of three 
biomarkers in metastatic breast cancer: ctDNA, CA 15-3, and CTCs. The result showed 
ctDNA can be detected in 29 of 30 women (97%); CTCs were detected in 26 of 30 
women (87%); CA 15-3 were detected in 21 of 27 women (78%). Not only did ctDNA 
show the best sensitivity of detection among three biomarkers, it can be used to assess 
treatment response [52]. 
Cell-free RNA (cfRNA) has piqued the interest of researchers in the last few 
years. The cfDNA in the circulation is thought to arise from cells undergoing necrosis or 
apoptosis. However, cfRNA can be released into circulation from living cells as well. 
Other than free-floating cfRNA, cfRNA can also come from extracellular vesicles, such 
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as exosomes. Exosomal RNA (exoRNA) has been employed to detect mutations along 
with ctDNA. The exoRNA has been characterized to contain microRNA, long non-
coding RNA (lncRNA), and mRNA [56-59]. Previous studies have shown that the 





1.3 Technologies to detect aberrations of circulating nucleic acids 
 
1.3.1 Next-generation sequencing 
Massively parallel sequencing, or next-generation sequencing (NGS), is a 
powerful tool with a variety of applications in cancer research. As it pertains to liquid 
biopsy, considering that the ratio of ctDNA to cfDNA, or the allele frequency (AF) of 
mutations is extremely low in most cases, the approaches of targeted sequencing for a 
subset of cancer-related genes are more favorable for ctDNA analysis. The reason being 
that a targeted-gene approach enables very high coverage of genes which gives better 
statistical confidence to detect lower AF mutations [65, 66]. There are two major targeted 
sequencing approaches: amplicon-based and hybrid capture enrichment. Amplicon-based 
method, such as AmpliSeq, performs highly multiplexed PCR simultaneously: hundreds 
of genes can be amplified at once. The demand on the quantity (as low as 1 ng) and 
quality of DNA is also low. The hybrid capture enrichment method, such as CAPP-seq, 
captures a panel of genes prior to amplification. Therefore, it requires higher input DNA, 
but the sensitivity of detection could be down to 0.1% of AF (Figure 8). Both of the 
approaches can include molecular barcodes (or unique molecular identifier; UMI) in the 
assays to reduce the false positive rate. WGS and whole exome sequencing (WES) had 
been conducted on cfDNA analysis but it is still not feasible for low AF detection.  
There are some advantages of applying NGS to liquid biopsy analysis. First, there 
is no need to know what mutations are present prior to sequencing. Second, the price of 
sequencing continues to drop with advances in technology. Third, due to sample barcode 
technology, more samples can be pooled and accommodated into a sequencing run. 
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Bioinformatic tools are used to separate sequencing reads afterwards according to sample 
barcodes. 
Currently, there are three major NGS platforms (Figure 9) available for liquid 
biopsy analysis on nucleic acids: Illumina, Ion Torrent, and Oxford Nanopore.  
Illumina uses the “sequencing-by-synthesis” technology. Every cycle it 
incorporates one corresponding florescence-labelled nucleotide according to the template 
sequence. Illumina offers a variety of different instruments, but at the high-end the read 
length can be up to 2 x 300 bp (paired-end reads), and the total output could be up to 
6000 Gb. 
The sequencing technology of Ion Torrent is based on pyrosequencing. Instead of 
recognizing individual nucleotides, Ion Torrent utilizes a semiconductor to detect one of 
the byproducts of pyrosequencing: proton. Since there is no florescence-labelled 
nucleotide, different nucleotides are introduced into sequencer one at a time: dGTP -
>dCTP ->dATP -> dTTP. The average read length is about 400 bp, depending on how 
many homopolymers in the sequence. The total output could be up to 10 Gb.  
Oxford Nanopore can perform single molecule sequencing. Its technology would 
be able to detect the change of current when a DNA molecule passing through a protein-
made nanopore. According to different instruments Oxford offers, the read length can be 
from hundreds upwards to 2 million bases. The total output could be up to 315 Gb. 
Although the Oxford Nanopore has the attractive feature of single molecule sequencing, 
which means no PCR errors will be generated, the sequencing error rate is still high. 
Considering the demand of high accuracy in the field of liquid biopsy, Oxford Nanopore 
















Figure 8: The dilution series analysis of CAPP-Seq. The author spiked in fragmented 






Figure 9: Three major next-generation sequencing platforms applied in liquid biopsy. 
Illumina HiSeq 4000, Ion Torrent, and Oxford Nanopore PromethION. Adapted from 





1.3.2 Digital PCR 
Digital PCR (dPCR) is a technology for quantification of DNA or cDNA 
molecules. Compared to conventional quantitative PCR (qPCR), dPCR can measure the 
actual number of molecules since dPCR can generate thousands of discrete reactions by 
forming water-oil emulsion droplets (Figure 10).  
Compared to NGS technology, dPCR has better sensitivity of detection (could be 
down to 0.01% depending on input material). However, to perform dPCR, the known 
mutations for the targets are required. Additionally, most of the dPCR reactions can 
detect only one mutation at a time. A few recent publications showed that multiplex 
dPCR can be performed in one reaction [68-72]. However, the number of mutations for 
detection is still limited. On the other hand, NGS technology for liquid biopsy can detect 
hundreds of genes at a time. Furthermore, NGS can also detect short insertion/deletion 
and rearrangement crossing the coding regions of the genome.   
Although there are some the limitations of dPCR, it is still a favorable method for 
validation and monitoring of known mutations in liquid biopsies, especially for extremely 
low allele frequency mutations. A number of studies have shown that using both dPCR 
and NGS on the same study can complement the needs of sensitivity as well as 









Figure 10: Workflow of digital PCR. Single DNA molecules are separated into individual 






1.4 Statement of purpose 
 
Standard imaging methods, such as CAT scan and MRI coupled with tissue 
biopsy, are the gold standard for clinical detection of recurrence. However, these 
technologies have limited capacity with respect to early detection of minimal residual 
disease (MRD), which precedes clinical recurrence and usually manifests in distant sites. 
My long-term goal is to reduce the rate of mortality in patients with chemoresistant 
TNBC through early detection and therapeutic intervention of patients who harbor MRD. 
Recently published data has demonstrated that in the metastatic setting, most breast 
cancer patients have detectable ctDNA in the plasma. I hypothesize that a highly sensitive 
next-generation sequencing assay using ctDNA and ctRNA to detect somatic mutations 
will significantly increase the sensitivity to detect MRD. I explored these hypotheses via 
the following sections: 
1. By sequencing and analyzing ctDNA to predict recurrence of TNBC after 
neoadjuvant chemotherapy, I observed that the overall sensitivity of detection was 
moderate with high specificity. I was able to detect rapid recurrence but not 
distant recurrence. 
2. By incorporating ctRNA with ctDNA in my sequencing assay, along with more 
sensitive sequencing methodology, I observed more mutant molecules using my 
combined ctDNA/ctRNA method, leading to an increased sensitivity to detect 
MRD.  
The following chapters will provide more details of the methods and results of these two 
aims.    
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Triple-negative breast cancer (TNBC) is pathologically defined by the absence of 
estrogen-receptor (ER), progesterone-receptor (PR), and human epidermal growth factor 
receptor 2 (HER2) over-expression [2-6].  On the pathological level, TNBC represents 
only 15-20% of all breast cancers, however, it results in a disproportionally higher rate of 
mortality [7]. On the molecular level, TNBCs are similar to a molecular subtype called 
“basal-like breast cancers”. Up to 80% of TNBCs are considered basal-like breast cancers 
[23, 24]. Compared to ER- & HER2-positive breast cancers, TNBCs are more likely to 
develop brain and visceral metastasis than bone metastasis [10]. They also have a higher 
likelihood to relapse within the first three years after chemotherapy and surgery, and have 
a shorter overall survival after the onset of metastatic disease [10]. A significant 
proportion of patients with TNBC are treated with neoadjuvant chemotherapy. A stark 
dichotomy exists in outcome based on response to neoadjuvant therapy. Around a third of 
patients will achieve a pathologic complete response (pCR) and continue to have a 
favorable overall survival outcome (94% at 3 years). On the contrary, two-thirds of 
patients have residual disease (RD) after neoadjuvant chemotherapy and are at a high risk 
of relapse leading to an inferior overall survival (68% at 3 years) [15]. Current standard 
method to diagnose recurrence of disease is imaging, such as CAT scan and MRI. 
However, imaging is not an ideal tool to detect MRD. Methods that can trace the 
presence of tumor-derived material in the circulation of patients who are technically 
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“disease-free” after neoadjuvant chemotherapy and surgery in the early time point are 
needed. They may be used to predict those patients whose disease will recur, and further 
help to determine which patients may need additional post-surgical therapy. 
An emerging method for non- or less-invasive cancer diagnosis is the analysis of 
“liquid biopsies” – the ability to detect tumor characteristics from the circulation, of 
which the most popular to date, is circulating tumor DNA (ctDNA). ctDNA is secreted 
into the circulation from the necrosis or apoptosis of tumor tissue, or from CTCs present 
in blood [55, 74]. It has been shown that ctDNA can be detected in many types of cancer 
[48-55]. In many cases, the fraction of ctDNA to total cell-free DNA (cfDNA) can be 
quite small (less than 1%) [75-77]. New technologies such as next-generation sequencing 
(NGS) and droplet digital PCR (ddPCR) can be used to detect low amounts of ctDNA. 
Because somatic mutations provide intrinsic specificity for nucleic acid material derived 
from tumor tissue, the presence of ctDNA implies the presence of disease.  
In this chapter, I utilized NGS technology to detect ctDNA from plasma samples 
of TNBC patients who had neoadjuvant chemotherapy and surgery. By detecting ctDNA, 





2.2 Materials and methods 
 
2.2.1 Clinical trial and correlative samples 
BRE09-146 was a prospective, multi-site, randomized Phase II clinical trial of 
cisplatin +/- PARP inhibition in TNBC patients who have residual disease after 
neoadjuvant chemotherapy. Eligibility criteria required residual disease, defined as either: 
(i) residual tumor >2 cm in the breast; (ii) lymph node involvement; or (iii) residual 
cancer burden (RCB) classification of II or III. Eligible patients were then randomized 
either to cisplatin for four cycles or cisplatin plus the PARP inhibitor Rucaparib for four 
cycles followed by maintenance Rucaparib for 24 weeks (Figure 11). Patients were 
enrolled on trial from March 2010 to May 2013. BRE09-146 is registered on 
ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/study/NCT01074970). For 
correlative analyses, clinical sites submitted tumor biopsies from the time of diagnosis, 
tumor from residual disease at the time of surgery, as well as whole blood prior to 
treatment. From the combination arm only (cisplatin + Rucaparib), plasma samples that 
were originally collected for pharmacokinetic analyses, were obtained at four pre-defined 
timepoints: Cycles 1 and 2 of the combination phase, and during Weeks 1 and 5 of the 
maintenance phase (detailed in Figure 11). For this correlative study of ctDNA, each 
evaluable patient had to have at least one tumor sample (with 60% or greater tumor 
cellularity), one whole blood sample, and one plasma sample submitted. Tumor DNA 
was isolated from formalin-fixed paraffin embedded (FFPE) tissue using the Qiagen 









Figure 11: Trial schema for BRE09-146.BRE09-146 was a Phase II clinical trial to evaluate 2-year disease-free survival (DFS) in 
TNBC patients, treated with either cisplatin (Arm A) or cisplatin in combination with PARP inhibitor Rucaparib (Arm B) after 
neoadjuvant chemotherapy. Tumor tissue, whole blood, and plasma from four time points after surgery were collected as indicated. In 
this trial, plasma samples were collected only in Arm B of (the area enclosed by the red rectangle). Plasma samples were collected at 
four timepoints: Cycles 1 and 2 of the combination phase, and during weeks 1 and 5 of the maintenance phase. 
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AutogenFlex Star instrument and the Flexigene AGF3000 blood kit at the Indiana 
Clinical and Translational Sciences Institute Specimen Storage Facility (ICTSI-SSF). 
Plasma DNA was isolated from 1 ml of plasma using the Qiagen QIAamp Circulating 
Nucleic Acid Kit (Qiagen, Cat. No. 55114). All DNA samples were quantified using the 
Qubit dsDNA HS Assay Kit (Life Technologies, Cat. No. Q32851). The trial and 
correlative studies were approved by the Indiana University Institutional Review Board 
(IRB); patients provided written informed consent prior to study entry including consent 
for blood samples for genomic analysis. The study was conducted in accordance with 
appropriate protocols established by Indiana University. 
 
2.2.2 Library preparation and sequencing 
DNA samples from each tumor, blood, and plasma sample underwent the same 
procedure for library preparation. DNA samples were amplified using a highly-
multiplexed polymerase chain reaction (PCR) that amplifies 134 genes that are well-
known to be mutated in cancer (Ion Ampliseq Oncomine Research Panel) (See Figure 12 
for details). Libraries were completed using the Ion Ampliseq Library Kit. The PCR 
program for amplification using the Ion Ampliseq Oncomine Research Panel was as 
follows: 1 x (99°C for 2 minutes), 21 x (99°C for 15 seconds, 60°C for 4 minutes), hold 
at 10°C. After amplifying DNA targets, DNA amplicons of the same sample were 
combined in one well of a 96-well plate. The two ends of the amplicons were then 
partially digested by FuPa Reagent (50°C for 10 minutes, 55°C for 10 minutes, 60°C for 
20 minutes, hold at 10°C up to 1 hour), followed by barcoded adapter ligation (22°C for 
30 minutes, 72°C at 10 minutes, hold at 10°C up to 1 hour). The libraries were then 
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purified by AMPure XP reagent at room temperature. The concentration of the eluted 
library was quantified by qPCR with the Ion Library Quantitation Kit (Cat. No. 4468802) 
using the Life Technologies 7900HT Fast Real-Time PCR System. The PCR program 
was as follows: 1 x (95°C for 20 seconds), 40 x (95°C for 1 second, 60°C for 20 
seconds). A library concentration of 50 picomolar or greater qualified for subsequent 
steps of Ion Chem emulsion PCR and templating and sequencing.  The libraries were 
subjected to emulsion PCR, and prepared for sequencing using the Life Technologies Ion 
Chef and the Ion PI IC 200 Kit (Life Technologies). Up to seven different barcoded 
libraries were loaded onto one Ion PI v2 BC chip to obtain appropriate coverage. 
Sequencing was carried out using a Life Technologies Ion Proton Next-generation 
sequencer (Figure 13). Each sample in my study was sequenced to at least 2500× 
coverage, with a median coverage of 6071× (range 2559×–13995×). Coverage details and 





Figure 12: The complete gene list of Ion AmpliSeq Oncomine Research Panel. This panel 
covers 134 of the most relevant cancer-related genes. Most of the genes are covered the 
hotspot region; more important tumor suppressor genes are full-length covered. This 






















Figure 13: Experimental workflow of mutation identification. DNA from tumor tissue, 
whole blood and plasma samples was extracted by a column-based method. Isolated 
DNA was amplified parallelly using the Ion Ampliseq Oncomine Cancer 
Panel. Amplicons from different samples of the same patient were further ligated by 
barcoded adapters. Libraries were then processed by an Ion Chef for preparation for 
sequencing on an Ion Proton next-generation sequencer using the Ion PI chip.  Mutations 
were called using the Torrent Suite v4.2.1 and Torrent Variant Caller v4.2.1.0 software, 







Diag Surg Timepoint 1 Timepoint 2 Timepoint 3 Timepoint 4
146-0004 TP53 Chr17:7577141 C -> T 10057 (13.1%) N/A 8691 N/A 11372 N/A 14858
146-0005 TP53 Chr17:7578492 C -> T N/A 6357 (46.1%) N/A 13493 (2.2%) 12902 8242 (49.4%) 14182
146-0008 TP53 Chr17:7577120 C -> T N/A 13404 (18.2%) 15581 N/A N/A 1124 15946
146-0010 TP53 Chr17:7577120 C -> T 5376 (9.0%) N/A N/A N/A 10379 13646 5409
146-0011 PIK3CA Chr3:178952085 A -> G N/A 2828 (65.6%) N/A N/A 7141 7107 8036
146-0011 TP53 Chr17:7579349 A -> G N/A 7368 (62.3%) N/A N/A 15910 11195 11190
146-0013 CDKN2A Chr9:21974792 G -> T 556 (38.5%) 618 (39.0%) 2245 (2.0%) 2282 1879 3609 (2.2%) 1392
146-0013 TP53 Chr17:7574003 G -> A 2042 (34.4%) 3313 (27.2%) 3359 (2.7%) 1930 4938 208 (4.8%) 4653
146-0014 TP53 Chr17:7579414 C -> T N/A 7854 (34.3%) 25802 N/A 16384 N/A 14594
146-0014 ERBB4 Chr2:212812097 T -> C N/A 892 (9.4%) 325 N/A 529 N/A 1449
146-0024 TP53 Chr17:7574030 G -> - 4415 (39.7%) N/A 6972 9449 7232 14244 5069
146-0024 PIK3CA Chr3:178952085 A -> G 4075 (3.5%) N/A 3122 3155 3686 4018 5241
146-0027 TP53 Chr17:7578212 G -> A 4334 (47.3%) N/A 6522 N/A 7625 57 6912
146-0027 SMARCB1 Chr22:24129284 G -> T 1804 (11.6%) N/A 896 N/A 736 0 1701
146-0028 TP53 Chr17:7578394 T -> C N/A 4778 (15.5%) N/A 5617 N/A N/A 11221
146-0031 TP53 Chr17:7578550 G -> A 4780 (45.8%) 3493 (32.1%) 5936 6033 5894 5698 5735
146-0044 PTCH1 Chr9:98241333 G -> A N/A 4546 (40.7%) 6449 N/A N/A 5255 7483
146-0044 TP53 Chr17:7577120 C -> T N/A 12909 (40.5%) 9597 N/A N/A 9546 12800
146-0044 TP53 Chr17:7578265 A -> G N/A 16301 (30.3%) 14863 N/A N/A 9737 15129
146-0048 PIK3CA Chr3:178947852 C -> T 24371 (64.0%) N/A N/A 8193 10534 19733 14339
146-0048 PIK3CA Chr3:178952085 A -> G 5065 (76.0%) N/A N/A 4578 3858 3029 5916
146-0048 RB1 Chr13:49037866 G -> C 174 (30.0%) N/A N/A 1251 756 1283 4911
146-0048 TP53 Chr17:7576851 A -> C 1271 (55.0%) N/A N/A 1986 1768 4361 2552
146-0055 TP53 Chr17:7577538 C -> T 4128 (60.6%) 6975 (67.5%) 17106 17612 N/A N/A 17171
146-0063 BIRC2 Chr11:102237807 T -> G N/A 2466 (14.1%) 2106 2084 2837 996 2564
146-0063 TP53 Chr17:7577105 G -> A N/A 12694 (35.7%) 2975 14984 17384 17158 13449
146-0064 CDKN2A Chr9:21971093 C -> T N/A 4678 (28.0%) N/A 7440 4844 3565 7164
146-0064 TSC2 Chr16:2129184 G -> A N/A 3563 (9.3%) N/A 7007 6245 6260 7532
146-0064 TP53 Chr17:7578212 G -> A N/A 5919 (46.8%) N/A 9016 3486 6581 8430
146-0066 NOTCH1 Chr9:139390869 G -> A N/A 25638 (18.8%) 1385 N/A 14098 N/A 14839
146-0066 TP53 Chr17:7579366 G -> T N/A 13467 (57.5%) 8516 N/A 12979 N/A 10506
146-0075 TP53 Chr17:7578458 G -> - 4873 (47.0%) N/A 18083 N/A 11346 13194 11316
146-0075 TP53 Chr17:7578289 C -> T 3032 (3.6%) N/A 75 N/A 4267 160 5035
146-0075 PIK3CA Chr3:178927462 G -> A 2234 (3.7%) N/A 40 N/A 5430 55 9960
146-0082 PIK3CA Chr3:178952085 A -> G N/A 2368 (65.6%) N/A 4524 8399 4830 4832
146-0082 FGFR1 Chr8:38282206 G -> A N/A 4518 (32.9%) N/A 8855 17608 10080 9841
146-0082 PTCH1 Chr9:98220584 A -> G N/A 5290 (22.6%) N/A 6999 10831 6096 8155
146-0082 GATA3 Chr10:8100889 A -> - N/A 4517 (32.4%) N/A 5528 9270 5360 4674
146-0082 CD44 Chr11:35223858 C -> G N/A 4683 (12.8%) N/A 6028 11155 6341 8735
146-0082 RB1 Chr13:48922002 A -> T N/A 971 (27.9%) N/A 1278 1542 725 3172
146-0082 TP53 Chr17:7577580 T -> C N/A 5766 (80.9%) N/A 7670 12230 8557 8202
146-0085 BRAF Chr7:140453136 A -> T N/A 4978 (22.0%) 2507 2404 1511 1650 4268
146-0085 AKT1 Chr14:105246551 C -> T N/A 2432 (36.1%) 2897 3162 3022 4140 2567
146-0085 TP53 Chr17:7576852 C -> T N/A 3083 (31.7%) 2713 2402 2798 2145 2417
146-0086 TP53 Chr17:7577594 AC -> - 5479 (36.4%) 5047 (37.2%) 9602 7795 N/A N/A 8977
146-0093 FGFR3 Chr4:1809344 G -> A 2600 (0.0%) 648 (10.3%) N/A 2682 N/A N/A 2911
146-0093 TP53 Chr17:7578526 C -> - 6425 (47.9%) 1860 (51.6%) N/A 13787 N/A N/A 8914
146-0094 TP53 Chr17:7574018 G -> A 4611 (27.0%) 5972 (0.0%) N/A N/A N/A 12370 7465
146-0102 AKT1 Chr14:105246551 C -> T 1291 (29.4%) N/A 11377 (0.4%) N/A N/A N/A 8984
146-0103 TP53 Chr17:7577046 C -> A 8008 (41.4%) N/A 15169 N/A 10291 11629 11425
146-0104 APC Chr5:112179214 G -> C N/A 8594 (31.5%) 10063 9472 6611 8687 11268
146-0104 TP53 Chr17:7577558 G -> - N/A 2403 (52.6%) 6312 6121 9014 6847 6239
146-0107 TP53 Chr17:7578508 C -> T N/A 10067 (18.1%) 14118 14067 15129 N/A 9347
146-0107 NF1 Chr17:29556965 T -> C N/A 847 (16.6%) 387 735 951 N/A 1002
146-0112 TP53 Chr17:7578203 C -> T 7691 (60.4%) 9184 (59.7%) 7676 (36.0%) N/A N/A N/A 8079
146-0114 CDK4 Chr12:58142091 G -> T 2095 (28.5%) N/A 1367 N/A N/A N/A 1678
146-0114 TP53 Chr17:7578270 ATGCTGAGGAGGGGCCAGACCTAAGAGCA -> - 1967 (22.1%) N/A 6566 N/A N/A N/A 8183
146-0116 PIK3CA Chr3:178916948 TTC -> - 2112 (15.9%) N/A N/A 674 605 N/A 3163
146-0116 PTEN Chr10:89685305 T -> G 2042 (38.1%) N/A N/A 160 107 N/A 1088
146-0116 NF1 Chr17:29587529 A -> T 5831 (15.5%) N/A N/A 1120 231 N/A 7620
146-0129 TP53 Chr17:7578236 A -> T 2762 (58.0%) N/A 5393 7068 5034 N/A 5259
146-0133 TP53 Chr17:7578263 G -> A N/A 6810 (12.0%) 10685 499 N/A 5319 14603
146-0135 PIK3R1 Chr5:67591145 TACTTGATGT -> - N/A 3992 (17.8%) N/A 4862 3679 2184 7423
146-0135 TP53 Chr17:7578515 T -> A N/A 6185 (23.0%) N/A 10196 9035 18749 8014
146-0135 NF1 Chr17:29665714 CCTAAAAGGC -> - N/A 1295 (9.8%) N/A 421 409 20 2883
ID Gene Position Plasma

















Table 1: The detailed sequencing results of coverage numbers, allele frequency, and tumor cellularity. N/A: not applicable: patients 
either did not have blood drawn, or sequencing failed at those timepoints.  
 
Diag Surg Timepoint 1 Timepoint 2 Timepoint 3 Timepoint 4
146-0004 TP53 Chr17:7577141 C -> T 10057 (13.1%) N/A 8691 N/A 11372 N/A 14858
146-0005 TP53 Chr17:7578492 C -> T N/A 6357 (46.1%) N/A 13493 (2.2%) 12902 8242 (49.4%) 14182
146-0008 TP53 Chr17:7577120 C -> T N/A 13404 (18.2%) 15581 N/A N/A 1124 15946
146-0010 TP53 Chr17:7577120 C -> T 5376 (9.0%) N/A N/A N/A 10379 13646 5409
146-0011 PIK3CA Chr3:178952085 A -> G N/A 2828 (65.6%) N/A N/A 7141 7107 8036
146-0011 TP53 Chr17:7579349 A -> G N/A 7368 (62.3%) N/A N/A 15910 11195 11190
146-0013 CDKN2A Chr9:21974792 G -> T 556 (38.5%) 618 (39.0%) 2245 (2.0%) 2282 1879 3609 (2.2%) 1392
146-0013 TP53 Chr17:7574003 G -> A 2042 (34.4%) 3313 (27.2%) 3359 (2.7%) 1930 4938 208 (4.8%) 4653
146-0014 TP53 Chr17:7579414 C -> T N/A 7854 (34.3%) 25802 N/A 16384 N/A 14594
146-0014 ERBB4 Chr2:212812097 T -> C N/A 892 (9.4%) 325 N/A 529 N/A 1449
146-0024 TP53 Chr17:7574030 G -> - 4415 (39.7%) N/A 6972 9449 7232 14244 5069
146-0024 PIK3CA Chr3:178952085 A -> G 4075 (3.5%) N/A 3122 3155 3686 4018 5241
146-0027 TP53 Chr17:7578212 G -> A 4334 (47.3%) N/A 6522 N/A 7625 57 6912
146-0027 SMARCB1 Chr22:24129284 G -> T 1804 (11.6%) N/A 896 N/A 736 0 1701
146-0028 TP53 Chr17:7578394 T -> C N/A 4778 (15.5%) N/A 5617 N/A N/A 11221
146-0031 TP53 Chr17:7578550 G -> A 4780 (45.8%) 3493 (32.1%) 5936 6033 5894 5698 5735
146-0044 PTCH1 Chr9:98241333 G -> A N/A 4546 (40.7%) 6449 N/A N/A 5255 7483
146-0044 TP53 Chr17:7577120 C -> T N/A 12909 (40.5%) 9597 N/A N/A 9546 12800
146-0044 TP53 Chr17:7578265 A -> G N/A 16301 (30.3%) 14863 N/A N/A 9737 15129
146-0048 PIK3CA Chr3:178947852 C -> T 24371 (64.0%) N/A N/A 8193 10534 19733 14339
146-0048 PIK3CA Chr3:178952085 A -> G 5065 (76.0%) N/A N/A 4578 3858 3029 5916
146-0048 RB1 Chr13:49037866 G -> C 174 (30.0%) N/A N/A 1251 756 1283 4911
146-0048 TP53 Chr17:7576851 A -> C 1271 (55.0%) N/A N/A 1986 1768 4361 2552
146-0055 TP53 Chr17:7577538 C -> T 4128 (60.6%) 6975 (67.5%) 17106 17612 N/A N/A 17171
146-0063 BIRC2 Chr11:102237807 T -> G N/A 2466 (14.1%) 2106 2084 2837 996 2564
146-0063 TP53 Chr17:7577105 G -> A N/A 12694 (35.7%) 2975 14984 17384 17158 13449
146-0064 CDKN2A Chr9:21971093 C -> T N/A 4678 (28.0%) N/A 7440 4844 3565 7164
146-0064 TSC2 Chr16:2129184 G -> A N/A 3563 (9.3%) N/A 7007 6245 6260 7532
146-0064 TP53 Chr17:7578212 G -> A N/A 5919 (46.8%) N/A 9016 3486 6581 8430
146-0066 NOTCH1 Chr9:139390869 G -> A N/A 25638 (18.8%) 1385 N/A 14098 N/A 14839
146-0066 TP53 Chr17:7579366 G -> T N/A 13467 (57.5%) 8516 N/A 12979 N/A 10506
146-0075 TP53 Chr17:7578458 G -> - 4873 (47.0%) N/A 18083 N/A 11346 13194 11316
146-0075 TP53 Chr17:7578289 C -> T 3032 (3.6%) N/A 75 N/A 4267 160 5035
146-0075 PIK3CA Chr3:178927462 G -> A 2234 (3.7%) N/A 40 N/A 5430 55 9960
146-0082 PIK3CA Chr3:178952085 A -> G N/A 2368 (65.6%) N/A 4524 8399 4830 4832
146-0082 FGFR1 Chr8:38282206 G -> A N/A 4518 (32.9%) N/A 8855 17608 10080 9841
146-0082 PTCH1 Chr9:98220584 A -> G N/A 5290 (22.6%) N/A 6999 10831 6096 8155
146-0082 GATA3 Chr10:8100889 A -> - N/A 4517 (32.4%) N/A 5528 9270 5360 4674
146-0082 CD44 Chr11:35223858 C -> G N/A 4683 (12.8%) N/A 6028 11155 6341 8735
146-0082 RB1 Chr13:48922002 A -> T N/A 971 (27.9%) N/A 1278 1542 725 3172
146-0082 TP53 Chr17:7577580 T -> C N/A 5766 (80.9%) N/A 7670 12230 8557 8202
146-0085 BRAF Chr7:140453136 A -> T N/A 4978 (22.0%) 2507 2404 1511 1650 4268
146-0085 AKT1 Chr14:105246551 C -> T N/A 2432 (36.1%) 2897 3162 3022 4140 2567
146-0085 TP53 Chr17:7576852 C -> T N/A 3083 (31.7%) 2713 2402 2798 2145 2417
146-0086 TP53 Chr17:7577594 AC -> - 5479 (36.4%) 5047 (37.2%) 9602 7795 N/A N/A 8977
146-0093 FGFR3 Chr4:1809344 G -> A 2600 (0.0%) 648 (10.3%) N/A 2682 N/A N/A 2911
146-0093 TP53 Chr17:7578526 C -> - 6425 (47.9%) 1860 (51.6%) N/A 13787 N/A N/A 8914
146-0094 TP53 Chr17:7574018 G -> A 4611 (27.0%) 5972 (0.0%) N/A N/A N/A 12370 7465
146-0102 AKT1 Chr14:105246551 C -> T 1291 (29.4%) N/A 11377 (0.4%) N/A N/A N/A 8984
146-0103 TP53 Chr17:7577046 C -> A 8008 (41.4%) N/A 15169 N/A 10291 11629 11425
146-0104 APC Chr5:112179214 G -> C N/A 8594 (31.5%) 10063 9472 6611 8687 11268
146-0104 TP53 Chr17:7577558 G -> - N/A 2403 (52.6%) 6312 6121 9014 6847 6239
146-0107 TP53 Chr17:7578508 C -> T N/A 10067 (18.1%) 14118 14067 15129 N/A 9347
146-0107 NF1 Chr17:29556965 T -> C N/A 847 (16.6%) 387 735 951 N/A 1002
146-0112 TP53 Chr17:7578203 C -> T 7691 (60.4%) 9184 (59.7%) 7676 (36.0%) N/A N/A N/A 8079
146-0114 CDK4 Chr12:58142091 G -> T 2095 (28.5%) N/A 1367 N/A N/A N/A 1678
146-0114 TP53 Chr17:7578270 ATGCTGAGGAGGGGCCAGACCTAAGAGCA -> - 1967 (22.1%) N/A 6566 N/A N/A N/A 8183
146-0116 PIK3CA Chr3:178916948 TTC -> - 2112 (15.9%) N/A N/A 674 605 N/A 3163
146-0116 PTEN Chr10:89685305 T -> G 2042 (38.1%) N/A N/A 160 107 N/A 1088
146-0116 NF1 Chr17:29587529 A -> T 5831 (15.5%) N/A N/A 1120 231 N/A 7620
146-0129 TP53 Chr17:7578236 A -> T 2762 (58.0%) N/A 5393 7068 5034 N/A 5259
146-0133 TP53 Chr17:7578263 G -> A N/A 6810 (12.0%) 10685 499 N/A 5319 14603
146-0135 PIK3R1 Chr5:67591145 TACTTGATGT -> - N/A 3992 (17.8%) N/A 4862 3679 2184 7423
146-0135 TP53 Chr17:7578515 T -> A N/A 6185 (23.0%) N/A 10196 9035 18749 8014
146-0135 NF1 Chr17:29665714 CCTAAAAGGC -> - N/A 1295 (9.8%) N/A 421 409 20 2883
ID Gene Position Plasma
Coverage (% mutation allele if applicable)
Blood
Mutation Tumor
Diag Surg Timepoint 1 Timepoint 2 Timepoint 3 Timepoint 4
146-0004 TP53 Chr17:7577141 C -> T 10057 (13.1%) N/A 8691 N/A 11372 N/A 14858
146-0005 TP53 Chr17:7578492 C -> T N/A 6357 (46.1%) N/A 13493 (2.2%) 12902 8242 (49.4%) 14182
146-0008 TP53 Chr17:7577120 C -> T N/A 13404 (18.2%) 15581 N/A N/A 1124 15946
146-0010 TP53 Chr17:7577120 C -> T 5376 (9.0%) N/A N/A N/A 10379 13646 5409
146-0011 PIK3CA Chr3:178952085 A -> G N/A 2828 (65.6%) N/A N/A 7141 7107 8036
146-0011 TP53 Chr17:7579349 A -> G N/A 7368 (62.3%) N/A N/A 15910 11195 11190
146-0013 CDKN2A Chr9:21974792 G -> T 556 (38.5%) 618 (39.0%) 2245 (2.0%) 2282 1879 3609 (2.2%) 1392
146-0013 TP53 Chr17:7574003 G -> A 2042 (34.4%) 3313 (27.2%) 3359 (2.7%) 1930 4938 208 (4.8%) 4653
146-0014 TP53 Chr17:7579414 C -> T N/A 7854 (34.3%) 25802 N/A 16384 N/A 14594
146-0014 ERBB4 Chr2:212812097 T -> C N/A 892 (9.4%) 325 N/A 529 N/A 1449
146-0024 TP53 Chr17:7574030 G -> - 4415 (39.7%) N/A 6972 9449 7232 14244 5069
146-0024 PIK3CA Chr3:178952085 A -> G 4075 (3.5%) N/A 3122 3155 3686 4018 5241
146-0027 TP53 Chr17:7578212 G -> A 4334 (47.3%) N/A 6522 N/A 7625 57 6912
146-0027 SMARCB1 Chr22:24129284 G -> T 1804 (11.6%) N/A 896 N/A 736 0 1701
146-0028 TP53 Chr17:7578394 T -> C N/A 4778 (15.5%) N/A 5617 N/A N/A 11221
146-0031 TP53 Chr17:7578550 G -> A 4780 (45.8%) 3493 (32.1%) 5936 6033 5894 5698 5735
146-0044 PTCH1 Chr9:98241333 G -> A N/A 4546 (40.7%) 6449 N/A N/A 5255 7483
146-0044 TP53 Chr17:7577120 C -> T N/A 12909 (40.5%) 9597 N/A N/A 9546 12800
146-0044 TP53 Chr17:7578265 A -> G N/A 16301 (30.3%) 14863 N/A N/A 9737 15129
146-0048 PIK3CA Chr3:178947852 C -> T 24371 (64.0%) N/A N/A 8193 10534 19733 14339
146-0048 PIK3CA Chr3:178952085 A -> G 5065 (76.0%) N/A N/A 4578 3858 3029 5916
146-0048 RB1 Chr13:49037866 G -> C 174 (30.0%) N/A N/A 1251 756 1283 4911
146-0048 TP53 Chr17:7576851 A -> C 1271 (55.0%) N/A N/A 1986 1768 4361 2552
146-0055 TP53 Chr17:7577538 C -> T 4128 (60.6%) 6975 (67.5%) 17106 17612 N/A N/A 17171
146-0063 BIRC2 Chr11:102237807 T -> G N/A 2466 (14.1%) 2106 2084 2837 996 2564
146-0063 TP53 Chr17:7577105 G -> A N/A 12694 (35.7%) 2975 14984 17384 17158 13449
146-0064 CDKN2A Chr9:21971093 C -> T N/A 4678 (28.0%) N/A 7440 4844 3565 7164
146-0064 TSC2 Chr16:2129184 G -> A N/A 3563 (9.3%) N/A 7007 6245 6260 7532
146-0064 TP53 Chr17:7578212 G -> A N/A 5919 (46.8%) N/A 9016 3486 6581 8430
146-0066 NOTCH1 Chr9:139390869 G -> A N/A 25638 (18.8%) 1385 N/A 14098 N/A 14839
146-0066 TP53 Chr17:7579366 G -> T N/A 13467 (57.5%) 8516 N/A 12979 N/A 10506
146-0075 TP53 Chr17:7578458 G -> - 4873 (47.0%) N/A 18083 N/A 11346 13194 11316
146-0075 TP53 Chr17:7578289 C -> T 3032 (3.6%) N/A 75 N/A 4267 160 5035
146-0075 PIK3CA Chr3:178927462 G -> A 2234 (3.7%) N/A 40 N/A 5430 55 9960
146-0082 PIK3CA Chr3:178952085 A -> G N/A 2368 (65.6%) N/A 4524 8399 4830 4832
146-0082 FGFR1 Chr8:38282206 G -> A N/A 4518 (32.9%) N/A 8855 17608 10080 9841
146-0082 PTCH1 Chr9:98220584 A -> G N/A 5290 (22.6%) N/A 6999 10831 6096 8155
146-0082 GATA3 Chr10:8100889 A -> - N/A 4517 (32.4%) N/A 5528 9270 5360 4674
146-0082 CD44 Chr11:35223858 C -> G N/A 4683 (12.8%) N/A 6028 11155 6341 8735
146-0082 RB1 Chr13:48922002 A -> T N/A 971 (27.9%) N/A 1278 1542 725 3172
146-0082 TP53 Chr17:7577580 T -> C N/A 5766 (80.9%) N/A 7670 12230 8557 8202
85 BRAF 7:140453136 A N/A 4978 (22.0%) 2507 2404 511 1650 26
146-0085 AKT1 r14:105246551  -> T / 2432 (36.1 ) 2897 3162 3022 4140 2567
146-0085 TP53 Chr17:7576852 C -> T N/A 3083 (31.7%) 2713 2402 2798 2145 2417
146-0086 TP53 Chr17:7577594 AC -> - 5479 (36.4%) 5047 (37.2%) 9602 7795 N/A N/A 8977
146-0093 FGFR3 Chr4:1809344 G -> A 2600 (0.0%) 648 (10.3%) N/A 2682 N/A N/A 2911
146-0093 TP53 Chr17:7578526 C -> - 6425 (47.9%) 1860 (51.6%) N/A 13787 N/A N/A 8914
146-0094 TP53 Chr17:7574018 G -> A 4611 (27.0%) 5972 (0.0%) N/A N/A N/A 12370 7465
146-0102 AKT1 Chr14:105246551 C -> T 1291 (29.4%) N/A 11377 (0.4%) N/A N/A N/A 8984
146-0103 TP53 Chr17:7577046 C -> A 8008 (41.4%) N/A 15169 N/A 10291 11629 11425
- 10 A C r5:112179214  -  C N/A 8594 (31.5%) 10063 72 6611 8687 112 8
10 TP5 17: 57755 G - N/A 2403 (52.6%) 631 6 21 9014 6847 6 39
- 10 : 508 C -  T N/A 10067 (18.1%) 14118 14067 151 9 N/A 9347
146-0107 NF1 Chr17:29556965 T -> C N/A 847 (16.6%) 387 735 951 N/A 1002
146-0112 TP53 Chr17:7578203 C -> T 7691 (60.4%) 9184 (59.7%) 7676 (36.0%) N/A N/A N/A 8079
146-0114 CDK4 Chr12:58142091 G -> T 2095 (28.5%) N/A 1367 N/A N/A N/A 1678
146-0114 TP53 Chr17:7578270 ATGCTGAGGAGGGGCCAGACCTAAGAGCA -> - 1967 (22.1%) N/A 6566 N/A N/A N/A 8183
146-0116 PIK3CA Chr3:178916948 TTC -> - 2112 (15.9%) N/A N/A 674 605 N/A 3163
146-0116 PTEN Chr10:89685305 T -> G 2042 (38.1%) N/A N/A 160 107 N/A 1088
146-0116 NF1 Chr17:29587529 A -> T 5831 (15.5%) N/A N/A 1120 231 N/A 7620
146-0129 TP53 Chr17:7578236 A -> T 2762 (58.0 ) /A 5393 7068 5034 N/A 5259
133 8263 G  A N/A 6810 (12.0%) 10685 499 N/A 5 19 14603
13 PIK R1 5:6 91145 TAC TGATGT -> - N/A 3 92 1 8 N/A 486 3679 2184 423
146-0135 TP53 r17:7578515 T -> A / 6185 (23.0 ) N/A 10196 9035 18749 8014
146-0135 NF1 Chr17:29665714 CCTAAAAGGC -> - N/A 1295 (9.8%) N/A 421 409 20 2883
ID Gene Position Plasma





2.2.3 Bioinformatics analysis 
Each sequencing run produced approximately 56–89 million reads. Reads 
underwent primary analysis using the Torrent Suite v4.2.1, which includes quality 
control, read trimming, and mapping to the human genome (hg19). Variant calling was 
performed using the Torrent Variant Caller v4.2.1.0. Somatic mutations were identified 
by comparing variants observed in the tumor sample that were not present in a matched 
blood sample. Identified somatic variants were then searched for in the plasma DNA 
sequencing using the Torrent Variant Caller. I also manually inspected called variants 
using the integrative genomics viewer [78, 79] to confirm the presence of variants and to 
rule out false positives. 
 
2.2.4 Statistical analysis 
Clinical follow-up data was provided by the trial contract research organization: 
Hoosier Cancer Research Network. The median follow-up for DFS for the entire trial was 
24 months. DFS analysis was performed using Cox regression (IBM SPSS Statistics 
version 24) and plotted using the Kaplan–Meier method (Graphpad Prism, GraphPad 
Software, Inc.). In univariate Cox regression analysis, the detection of ctDNA was 
significantly associated with inferior DFS. In multivariate Cox regression, when adding 
RCB and number of positive lymph nodes as covariates, the detection of ctDNA was 
independently associated with DFS (see Results). Age, race, tumor grade, and Eastern 
Cooperative Oncology Group (ECOG) performance status were not associated with DFS, 






2.3.1 Comprehensive genomic profiling of tumor and normal tissue 
 
2.3.1.1 Patient and sample selection 
One-hundred thirty-five patients were enrolled on the BRE09-146 clinical trial. 
Patient characteristics, including: median age, race, neoadjuvant chemotherapy, radiation 
therapy, median residual lymph node positivity (LN+), and median RCB are detailed in 
Table 2. All patients received multiple agent neoadjuvant chemotherapy, with the vast 
majority receiving a combination of anthracycline, cyclophosphamide, and paclitaxel, 
followed by surgery and radiotherapy (Table 2). TNBC patients who completed 
neoadjuvant therapy and had significant residual disease were randomized to either 
cisplatin monotherapy or the combination of cisplastin plus rucaparib. Plasma samples 
used for the analysis of ctDNA were only collected in patients enrolled in the 
combination arm (Figure 11). Details of patient selection included in this study are 
outlined in the Consolidated Standards for Reporting Trials (CONSORT) diagram. In 
total, 38 patients with matched tumor tissue, blood, and at least one plasma sample were 
successfully sequenced (Figure 14). 
 
2.3.1.2 Identification of somatic mutations in the primary tumors 
I first identified somatic mutations present in the primary tumor by identifying 
variants from tumor sequencing that were not present in the matched normal blood. Of 
the 38 patients described above, I successfully identified at least one somatic mutation in 
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87% of patients (33 of 38; Figure 15), and two or more somatic mutations in 55% of 
patients (21 of 38; Figure 15). Among those who had somatic mutation(s) identified, 31 
patients had TP53 mutations (33 TP53 mutations in total; two patients had dual TP53 
mutations). Ten out of 38 patients carried genetic alterations in the genes involved in 
PI3K signaling pathway. Among those, PIK3CA was the most common gene with 
genetic alterations (six patients), followed by AKT1 (two patients), PIK3R1, and PTEN 
(one patient each). The high-rate of TP53 and PI3K mutations is congruent with 
published data from the The Cancer Genome Atlas (TCGA)[80], which observed the 
same pattern in TNBC tumors. 
 
2.3.2 Detection of tumor-related mutations in plasma sequencing 
I then searched for the somatic mutations identified from the primary tumors in 
the matched plasma samples. Of the 33 patients who had a somatic mutation identified in 
their primary tumor, I was able to detect somatic mutations in the plasma of four patients 
(three TP53 mutations, one AKT1 mutation, and one CDKN2A mutation). All four 
patients had recurrence of their disease (100% specificity), but sensitivity was limited to 
detecting only 4 of 13 patients who relapsed (31% sensitivity). Figure 16 to Figure 19 
details the time-course of the mutational allele frequency for these four patients. In 
patient 146-0005 (Figure 16), a TP53 mutation (Chr17:7578492, C to T) was detected in 
timepoint 2 and 4 plasma samples. A similar pattern (timepoint 1 and 4) was observed in 
patient 146-0013 who had a different TP53 mutation (Chr17:7574003, G to A) and a 
CDKN2A mutation (Chr9:21974792) (Figure17). I was also able to detect somatic 
mutations in plasma samples from the other two patients who had only one timepoint 
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plasma sample available (146-0102, AKT1 mutation, Chr14:105246551, C to T; 146-
0112, TP53 mutation, Chr17:7578203, C to T) (Figure 18 and Figure 19). All mutations 
were located in exonic regions. Interestingly, all four patients had a rapid recurrence: 
average of 4.6 months (0.3, 4.0, 5.3, and 8.9 months). The lead time of detection of the 











Subjects from arm B 
for this study 
(n  = 38)
Median age 48 (27–69) 47 (21–75) 47 (21–66)
a. African American 20.00% 18.60% 13.20%
b. White 75.40% 72.90% 73.70%
c. Asian 1.50% 4.30% 7.90%
d. Others 3.10% 4.30% 5.30%
a. Anthracycline 89.20% 88.60% 92.10%
b. Cyclophosphamide 95.40% 90.00% 92.10%
c. Taxane 95.40% 92.90% 92.10%
d. Carboplatin 1.50% 10.00% 10.50%
e. Unknown 3.10% 2.90% 0%
Radiation therapy 87.70% 85.70% 84.20%
Median residual lymph node positivity (LN+) 1 (0–15) 1 (0–38) 1 (0–38)









Figure 14: CONSORT diagram. There were 135 patients enrolled in BRE09-146. In this 
study, I focused on 70 patients from Arm B. In Arm B, 27 patients did not have matched 
tumor tissue, whole blood, and at least one plasma collection and were excluded from this 
study leaving an N = 43. A further five patients were removed due to the inability to 








Figure 15: Somatic mutations identified from sequencing of tumor tissues. Among the 38 
patients in my study, 33 of them had at least one somatic mutation identified (87%); 21 of 
them had two or more somatic mutations (55%). TP53 mutations were the most prevalent 
in this study, followed by PIK3CA pathway mutations. Notably, there were 14 different 
mutations exclusively present in individual patients, representing the genomic 







Figure 16: Longitudinal allele frequency tracking of ctDNA mutations in patient 146-
0005. The same TP53 mutation was observed at 2 out of 3 timepoints. The increasing 
allele frequency of ctDNA was observed before clinically recurrence was diagnosed. I 






Figure 17: Longitudinal allele frequency tracking of ctDNA mutations in patient 146-
0013. Two mutations were detected from different genes: TP53 and CDKN2A. Both 
mutations were observed at 2 out of 4 timepoints. The increasing allele frequencies of 
ctDNA were also observed in both genes before clinically recurrence was diagnosed. I 






Figure 18: Longitudinal allele frequency tracking of ctDNA mutations in patient 146-
0102. AKT1 mutation was observed at the only available timepoint. I was able to detect 






Figure 19: Longitudinal allele frequency tracking of ctDNA mutations in patient 146-
0112. TP53 mutation was observed at the only available timepoint. I was able to detect 




2.3.3 Correlation of early recurrence and presence of tumor DNA in plasma 
A Kaplan–Meier plot demonstrates that the patients who had ctDNA detected in 
their plasma, had a significantly inferior DFS compared to patients where ctDNA was not 
detected (p < 0.0001, median DFS: 4.6 mos. vs. not reached (NR); hazard ratio 
(HR) = 12.6, 95% confidence interval (CI): 3.06–52.2) (Figure 20). In multivariate Cox 
regression analysis, with the addition of RCB and number of positive lymph nodes as 
covariates, the detection of ctDNA remained independently associated with inferior DFS 






Figure 20: Kaplan–Meier plot: disease-free survival stratified by presence of tumor 
mutation in plasma. Four patients from this study who had mutation identified from 
plasma samples relapsed rapidly (0.3, 4.0, 5.3, and 8.9 months). The yellow 
line represents patients with detectable ctDNA in plasma. The blue line represents 
patients with no detectable ctDNA in plasma. The difference in median DFS between 
patients with detectable ctDNA vs. those without was statistically significant (p < 0.0001, 






TNBC patients who do not achieve a pCR to neoadjuvant chemotherapy are at a 
high-risk of recurrence from their disease. Unfortunately, there is no FDA approved 
standard-of-care for this post-neoadjuvant setting. However, reported results from the 
CREATE-X trial [81] demonstrated an improvement in 2-year DFS and OS with the use 
of post-neoadjuvant capecitabine for women with HER2-negative breast cancer with 
residual disease after neoadjuvant chemotherapy. A subgroup analysis revealed an 
improved benefit for TNBC patients [81]. Given the clinical scenario, determining those 
patients who will relapse using methods that can detect the presence of tumor-derived 
material, even when the patient is technically “disease-free” after surgery, can help 
predict which patients will recur, and potentially design therapeutic strategies for this 
population. Although tissue biopsy remains the standard approach for determining the 
presence of tumor, the liquid biopsy using ctDNA is emerging as a complimentary 
method. Because somatic mutations provide intrinsic specificity for nucleic acid material 
derived from tumor tissue, the presence of ctDNA implies the presence of disease. In the 
evolving realm of circulating biomarkers, a recent study suggests that ctDNA may confer 
the highest sensitivity. Dawson et al. compared the use of circulating antigen 15-3, CTCs 
and ctDNA for blood-based detection, and demonstrated that the measurement of ctDNA 
possessed the highest sensitivity for monitoring metastatic breast cancer [52]. While the 
vast majority of ctDNA studies have focused on patients with metastatic disease, in this 
study I focused on patients who are in the curative setting. The patients in my cohort are 
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disease free by standard clinical assessment, but they are known to be at a high-risk of 
relapse. 
In my study, I searched for somatic mutations in plasma-sequencing data that 
were first identified in the matched primary tumor. Congruent with published studies of 
genomic sequencing of TNBCs, I observed a high-rate of TP53 and PI3K pathway 
mutations [80]. Of 33 evaluable patients, 13 had a clinical relapse, and of those, I was 
able to detect ctDNA in 4. Of interest, all four of these patients had a rapid recurrence, 
ranging from 0.3 months to 8.9 months. The lead-time from the first-detection of ctDNA 
to clinical recurrence ranged from 0.07 months to 8.87 months. I was not able to detect 
ctDNA in patients with distant recurrence. Further, I was unable to detect ctDNA in five 
patients who had a recurrence in <12 months. While all patients in which ctDNA was 
observed did have a rapid recurrence, the low sensitivity to detect distant, and in some 
cases rapid recurrence, highlights its limitations. Because the ability to detect ctDNA is 
proportional to the number of mutated molecules in the circulation; disease burden, and 
the volume of plasma that is sampled are important factors that regulate sensitivity. My 
study represents a “worst-case scenario” in which there is no detectable disease burden at 
enrollment, and only 1 mL of plasma in which to perform my studies. Even in this 
setting, I was able to detect some patients with rapid recurrence. Given the retrospective 
nature of my study with a limited sample size, however, a prospective trial to prove 
clinical utility is well warranted. 
A pivotal study by Garcia-Murillas et al.in a cohort of early breast cancer patients 
demonstrated that detection of ctDNA showed a similar pattern of rapid recurrence [51]. 
A similar study by Olsson et al. showed that serial ctDNA sampling in patients with 
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primary breast cancer can reach an average lead time of 11 months before the occurrence 
of metastatic disease [82]. Key differences between my studies and theirs is the specific 
enrichment of a TNBC population in my study, and my use of NGS vs. ddPCR for 
ctDNA detection. While ddPCR has increased sensitivity, it requires the generation of 
patient-specific custom assays, and usually it can only detect one mutation at a time. 
Thus, NGS has the advantage of being more generalizable for the application of ctDNA 
detection to a breast cancer population. Lastly, another study by Riva et al., the 
investigators were unable to detect ctDNA in TNBC patients after surgery using ddPCR 
[73]. This observation along with mine highlights the importance of serial sampling after 
surgery. 
To summarize this chapter, next-generation ctDNA-sequencing of TNBC patients 
after neoadjuvant chemotherapy and surgery can detect rapid-recurrence but sensitivity to 
detect distant recurrence is limited. The following directions can be considered to 
increase sensitivity of detection: improved or novel extraction methodologies; sequencing 
chemistries that attempt to provide increased enrichment of mutated DNA molecules (i.e., 
CAPP-Seq) [67]; sensitive nucleic acid detection using CRISPR-Cas13a along with 
isothermal amplification [83]; or the combination of ctDNA with other blood-based 
biomarkers such as cfRNA (mRNA, miRNA, and lncRNA), or exosomal protein [84]. 
In next chapter, it will be demonstrated that how I incorporated ctRNA into ctDNA 
detection, along with enhanced extraction methodology and improved chemistries for 




Chapter 3: Co-detection of circulating tumor DNA and circulating tumor RNA to 




With recent advances in next-generation sequencing technologies, significant 
progress in ctDNA-based cancer detection has been made. Although multiple studies 
have demonstrated that the progression of metastatic breast cancer can be tracked using 
ctDNA [51, 85, 86], few studies have been published demonstrating its use for detection 
of MRD [51, 87]. Detecting MRD is an evolving and powerful application of this 
technology. In addition, no studies to my knowledge have been conducted exploring the 
potential of the combined analysis of ctDNA along with ctRNA. The research proposed is 
innovative as it leverages cutting-edge and multi-faceted technologies to detect 
circulating tumor nucleic acids, thus providing unprecedented detection of MRD in early-
stage TNBC patients. 
As detailed in Chapter 2, using plasma samples from a completed Phase II clinical 
trial of TNBC patients with residual disease after neoadjuvant chemotherapy, I applied 
next-generation sequencing to determine if detection of ctDNA can be used as a predictor 
of relapse in this high-risk patient population. I observed that next-generation ctDNA-
sequencing can detect rapid-recurrence but sensitivity to detect distant recurrence is 
limited. The lack of sensitivity for ctDNA detection can be attributed to both biological 
and technical factors. In regards to biology, the ability to detect ctDNA is proportional to 
the number of mutated molecules in the circulation, disease burden, and the volume of 
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plasma that is sampled. Further, for ctDNA to be present, DNA must be released by 
dying tumor cells [55]. For patients whose disease does not recur for a long period of 
time, microscopic deposits of tumor cells can remain in a dormant state and not undergo 
cellular turnover. RNA however is actively released from live cells in the form of 
extracellular vesicles known as exosomes. Here I utilize RNA to call mutations. In this 
chapter I will show that the number of detectable mutated molecules can be increased by 
simultaneous detection of ctRNA and ctDNA using both ddPCR and NGS. In regards to 
technical limitations, a particular assay must be able to detect very low concentrations of 
mutated molecules in the presence of a large concentration of wild-type molecules. 
Recent advances in library preparation chemistries have now enabled sensitivity to as low 
as 0.1% allele frequency. For this chapter, I will be employing a newly available 
chemistry called Avenio (also known as CAPP-seq) which combines a capture-based 
library preparation along with single molecule barcoding, to achieve high sensitivity [67, 
88, 89]. In this chapter, I aim to improve both the biological and technical barriers to 
achieving higher sensitivity for MRD detection by: (1) incorporation of ctRNA in 
addition to ctDNA in the same sequencing reaction for simultaneous detection of somatic 
mutations; (2) applying the novel Avenio method for ctRNA and ctDNA library 
preparation which uses a capture-based methodology to enrich mutated regions of the 
genome followed by single-molecule barcoding and sequencing to achieve ultra-low 
allele frequency detection. I will also show the enhanced cell-free nucleic acid extraction 




3.2 Materials and methods 
 
3.2.1 ddPCR to assess the contribution of ctRNA to ctDNA on known mutations 
 Plasma samples were obtained from metastatic cancer patients requested from the 
IU Simon Cancer Center Tissue Bank. Circulating nucleic acids were isolated from 8 ml 
of plasma using the Qiagen QIAamp Circulating Nucleic Acid Kit (Qiagen, Cat. No. 
55114), then split into two groups: (1) ctDNA detection only, (2) ctDNA plus ctRNA 
detection. In the ctDNA + ctRNA group, circulating nucleic acids underwent reverse 
transcription using SuperScript IV VILO Master Mix (Thermo Fisher Scientific, Cat. No. 
11756050) to obtain cDNA from cfRNA. ddPCR probes and assays were designed to 
detect the two mutations (TP53 R282W, BioRad Cat. No. 10049550, dHsaMDV2516902; 
KRAS Q61H, BioRad Cat. No. 10049550, dHsaMDV2010133) that the patient harbored. 
The ddPCR experiments were performed using QX200 Droplet Digital PCR System. 
 
3.2.2 Clinical samples for ctDNA/ctRNA co-detection using NGS technology 
 To evaluate the feasibility of co-detecting ctDNA and ctRNA using NGS 
technology, I conducted the experiment using plasma samples from six metastatic breast 
cancer patients with known mutations of ctDNA identified previously by Foundation 
Medicine (FoundationACT). All plasma samples (4 ml of plasma for each patient) were 
extracted using the Qiagen QIAamp Circulating Nucleic Acids kit (Qiagen, Cat. No. 
55114). Each extracted sample was split into two: (1) to be used for detection of ctDNA 
only; and (2) for detection of ctDNA + ctRNA. Reverse transcription was performed only 
on the samples in the ctDNA +ctRNA group. SuperScript IV VILO Master Mix (Thermo 
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Fisher Scientific, Cat. No. 11756050) was used to obtain first-stranded cDNA. Second-
stranded cDNA was synthesized by following the “Second-Strand Synthesis” portion of 
SuperScript™ Double-Stranded cDNA Synthesis Kit (Thermo Fisher Scientific, Cat. No. 
11917010) to obtain double-stranded cDNA. Measurement of DNA and DNA+cDNA 
were quantified using the Qubit dsDNA HS Assay Kit (Life Technologies, Cat. No. 
Q32851). All samples underwent Avenio ctDNA library preparation. 
 After confirming that the co-detection of ctDNA and ctRNA can accommodate 
NGS technology using Avenio capture-based methodology, I then moved on to the 
additional banked plasma samples from BRE09-146 described in Chapter 2. Plasma DNA 
was isolated from 1 ml of plasma using the Qiagen QIAamp Circulating Nucleic Acid Kit 
(Qiagen, Cat. No. 55114). All extracted cell-free nucleic acids underwent reverse 
transcription, second-stranded cDNA synthesis, and quantification as described 
previously. All samples underwent Avenio ctDNA library preparation. 
 
3.2.3 The Avenio (CAPP-Seq) methodology for ultra-low allele frequency detection 
 The Avenio technology enables low allele frequency detection of point mutations, 
indels, fusions, and copy number variation from plasma-derived ctDNA. The Avenio 
chemistry begins by attaching a unique molecular barcode to each DNA fragment. This 
assists in downstream bioinformatics analysis to eliminate false positives caused by PCR 
errors. Subsequent to molecular barcoding, genes of interest are then captured using a 
liquid hybrid capture (Figure 21). In this chapter, I used the Avenio Expanded Panel 
which contains probes to hybrid capture 77 cancer genes known to be commonly mutated 
in cancer (Table 3). This panel includes genes commonly known to be mutated in TNBC, 
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including: TP53, PIK3CA, PTEN, and RB1 [80]. Single nucleotide point mutations can 
be detected down to 0.1% allele frequency (Figure 8). Indels and fusions are detectable to 
1.0% allele frequency and CNVs down to 2.3 copies (data provided by the manufacturer 
Roche). 
 
3.2.4 Library Preparation and Sequencing 
Extracted cfDNA and reverse transcribed cDNA underwent library preparation 
using Roche Avenio ctDNA Expanded Kit. DNA fragments were ligated with adapters 
containing single-molecule molecular barcodes, which enables a reduction in false 
positives during analysis. This was followed by capture-based target enrichment of 77 
cancer-related genes. Samples were sequenced with 2x150 bp paired-end configuration 
on an Illumina NextSeq 500 using the NextSeq 500/550 High Output kit v2 (300 cycles 
and 400 million reads per flowcell) at the Indiana University Center for Medical 
Genomics. Each sample was sequenced to an average of 60 million reads per sample. A 
phred quality score (Q score) is used to measure the quality of sequencing. A Q30 (99.9% 
base call accuracy) of 90% or higher in sequencing reads is expected. 
 
3.2.5 Bioinformatics Analysis 
 Each sample from sequencing had an average of 60 million reads.  Reads 
underwent primary analysis using the Avenio ctDNA Analysis Server which includes 
quality control, read trimming, demultiplexing, mapping to the human genome (hg19), 
and variant calling. Variants and allele frequencies are reported by the server and can 
then be filtered and a report generated. The manual analysis was performed to validate 
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the expected mutations which were not reported out in the standard pipeline using de-
duplicated BAM files on Integrative Genomics Viewer [78, 79].  
 
3.2.6 Statistical Analysis 
Clinical follow-up data has already been provided by the trial contract research 
organization (CRO): Hoosier Cancer Research Network. The median follow-up for DFS 
for the entire trial is 48 months. I anticipated that the number of patients in which MRD is 
detected will be higher in the ctRNA+ctDNA samples as compared to ctDNA alone. I 
also anticipated a proportion of patients will have MRD detected at an earlier timepoint 
using ctRNA+ctDNA compared to ctDNA alone. I also calculated my sensitivity to 
predict patients who had a clinical relapse of their disease. The specificity and the DFS 
analysis will be performed using Cox regression (IBM SPSS Statistics version 24) and 
plotted using the Kaplan-Meier method (Graphpad Prism, GraphPad Software, Inc.) after 


















Figure 21: Roche Avenio ctDNA library preparation workflow. cfDNA+cfcDNA or 
cfDNA-only as input for end repair and adapter ligation, where the molecular barcodes 
incorporate into each DNA molecules before amplification. During the target enrichment 
step, 77 genes included in Expanded Kit will be captured and amplified prior to 






Table 3: The targets of Roche Avenio ctDNA Expanded Kit. 77 genes are included in this 
panel to detect point mutations, indels, fusions, and copy number variations. The panel 






3.3.1 Proof of concept study in metastatic cancer  
 
3.3.1.1 ddPCR 
I recently generated preliminary data using digital droplet (ddPCR) on a plasma 
sample from a patient with metastatic cancer. This particular patient harbored a known 
TP53 R282W mutation and a KRAS Q61H mutation. The ddPCR probes used to detect 
both mutations were designed to be contained within a single exon, and did not cross 
splice junctions. As can be seen in Figure 22, the combination of ctRNA along with 
ctDNA resulted in a significant increase in the absolute copy number of mutated 
molecules (TP53 R282W = 47.9% increase; KRAS Q61H = 83.9% increase). 
To corroborate my observations, data presented at the 2015 American Society of 
Clinical Oncology annual meeting by Exosome Diagnostics demonstrated that by using a 
proprietary column-based extraction strategy (known as EXO52), cell-free DNA as well 
as exosomal RNA can be simultaneously captured. When analyzed, the addition of 
reverse-transcribed exosomal RNA to cell free DNA significantly increases the number 
of gene copies that can be profiled from plasma samples [90] (Figure 23a). Further data 
from a similar study demonstrated that the increase in copy number of mutated molecules 
by combining ctRNA with ctDNA can consistently occur at multiple timepoints from the 
same patient. As seen in Figure 23b, a significant Increase in copy number of mutated 












Figure 22: The ddPCR experiment on DNA or DNA + cDNA. Copy number of mutated 








Figure 23: ddPCR to detect ctRNA from other studies. (a) Absolute quantification of 
extracted gene copies. Comparison of two fractions isolated from 86 different patient 
samples: cell-free DNA (cfDNA) and cfRNA+cfDNA (EXO52). In these three genes, the 
added molecules from RNA are around 100% (dotted line). (b) An example from serial 
blood sampling of a melanoma patient being treated with ipilimumab. Y-axis represents 
concentration of mutated copies of BRAF per milliliter of plasma. X-axis represents 
treatment timepoints. As can be seen across timepoints, ctRNA is additive to ctDNA by 







3.3.1.2 Comparison of ctDNA-only and ctDNA/ctRNA co-detection on metastatic 
breast cancer samples using NGS technology 
Plasma samples from six metastatic breast cancer patients were previously 
sequenced by Foundation Medicine (FoundationACT) to detect ctDNA. I used additional 
banked plasma samples for this proof of concept study. I was able to identify at least one 
mutation in both ctDNA-only and ctDNA/ctRNA groups from all six patients. The 
mutations identified here were concordant to those previously reported by 
FoundationACT. Five patients had one mutation detected: (1) 0534-417, TP53 
p.Arg248Gln; (2) 0534-419: PIK3CA p.His1047Arg; (3) 0534-427: PIK3CA 
p.His1047Arg; (4) 0534-435: TP53 p.Arg175His; (5) 0534-469: ERBB2 insertion 
(A775_G776insYVMA). Patient 0534-430 had seven TP53 mutations detected 
(p.Arg306*, p.Arg273Cys, p.Gly245Ser, p.Arg213*, p.Pro152Leu, p.Arg110Cys, and 
p.Gly105Ser).  
The numbers of mutant molecules in the ctDNA/ctRNA co-detection group were 
all higher than the corresponding mutations in ctDNA-only group. The average 
percentage increase was 67% (range=2.8%-385%). The allele frequencies among all 
mutations were similar to the samples previously sequenced by Foundation Medicine 
(FoundationACT) (Figure 24-29; Table 4). The copy number of mutation was not 





Figure 24: Comparing the sequencing result of patient 0534-417. More mutant molecules 
(TP53) were detected in ctDNA + ctRNA group per ml of plasma. Previous sequencing 
result from Foundation Medicine (FM) confirmed the same mutation with similar allele 






Figure 25: Comparing the sequencing result of patient 0534-419. More mutant molecules 
(PIK3CA) were detected in ctDNA + ctRNA group per ml of plasma. Previous 
sequencing result from FM confirmed the same mutation with similar allele frequency. 
















Figure 26: Comparing the sequencing result of patient 0534-427. More mutant molecules 
(PIK3CA) were detected in ctDNA + ctRNA group per ml of plasma. Previous 
sequencing result from FM confirmed the same mutation with similar allele frequency. 
















Figure 27: Comparing the sequencing result of patient 0534-435. More mutant molecules 
(TP53) were detected in ctDNA + ctRNA group per ml of plasma. Previous sequencing 
result from FM confirmed the same mutation with similar allele frequency. Copy number 























































Figure 28: Comparing the sequencing result of patient 0534-469. More mutant molecules 
(ERBB2) were detected in ctDNA + ctRNA group per ml of plasma. Previous sequencing 
result from FM confirmed the same mutation with similar allele frequency. Copy number 
















Figure 29: Comparing the sequencing result of patient 0534-430. More mutant molecules (TP53) were detected in ctDNA + ctRNA 
group per ml of plasma among all seven TP53 mutations. Previous sequencing result from FM confirmed the same mutations with 






Table 4: Patient-specific mutations and corresponding allele frequencies and mutant 
copies per ml plasma. Allele frequencies were similar to each other of the same mutation. 
The numbers of copies per ml of plasma were all higher in the ctDNA/ctRNA group. 
  
ctDNA ctDNA/ctRNA FM ctDNA ctDNA/ctRNA Increased %
0534-417 TP53 p.Arg248Gln 0.46% 1.01% 0.73% 7.3 35.4 384.93%
0534-419 PIK3CA p.His1047Arg 0.74% 0.62% 0.85% 176 181 2.84%
0534-427 PIK3CA p.His1047Arg 1.24% 1.73% 1.80% 26.2 50.3 91.98%
0534-435 TP53 p.Arg175His 1.48% 1.35% 0.99% 44.9 61.1 36.08%
0534-469 ERBB2 ERBB2 insertion 10.20% 11.10% 10.80% 310 521 68.06%
p.Arg306* 10.21% 10.41% 10.70% 3370 4050 20.18%
p.Arg273Cys 2.47% 2.64% 2.80% 816 1030 26.23%
p.Gly245Ser 1.98% 1.99% 3.10% 652 775 18.87%
p.Arg213* 9.98% 10.64% 10.80% 3290 4140 25.84%
p.Pro152Leu 0.92% 1.17% 1.10% 305 455 49.18%
p.Arg110Cys 3.06% 3.17% 3.60% 1010 1230 21.78%








3.3.2 Co-detection of mutated molecules in plasma sequencing of early TNBC 
I then performed the co-detection strategy on additional banked plasma samples 
from BRE09-146. To assess if the sensitivity of detection would increase, I focused on 
plasma samples from 13 patients who had a recurrence. In total, forty-three plasma 
samples were sequenced. Two of those forty-three samples failed due to insufficient input 
for library preparation.  
 In the reports generated from standard pipeline of Avenio ctDNA Analysis 
Server, I was able to detect somatic mutations in the plasma of five patients (four TP53 
mutations, one ATK1 mutation, and one CDKN2A mutation). Figure 30 to Figure 34 
detail the time-course of mutational allele frequency and copy of mutation per ml of 
plasma for these five patients. In patient 146-0005 (Figure 30), a TP53 mutation 
(Chr17:7578492, C to T) was detected in all four timepoints. A similar pattern was 
observed in patient 146-0013 who had a different TP53 mutation (Chr17:7574003, G to 
A; all three timepoints) and a CDKN2A mutation (Chr9:21974792, G to T; timepoint 1 
and 3) (Figure31); in patient 146-0102 who had an AKT1 mutation (Chr14:105246551, C 
to T) in three of four timepoints (Figure 32); in patient 146-0135 who had a TP53 
mutation (Chr17:7578515, T to A) in two of four timepoints (Figure 33). I was also able 
to detect somatic mutations in plasma sample from one patient who had only one 
timepoint plasma sample available (146-0112, TP53 mutation, Chr17:7578203, C to T) 
(Figure 34). All five patients had a rapid recurrence: average of 4.98 months (0.3, 4.0, 
5.3, 6.4, and 8.9 months). The lead time of detection of the mutation in the plasma to 





Figure 30: Longitudinal allele frequency tracking of ctDNA/ctRNA mutations in patient 






Figure 31: Longitudinal allele frequency tracking of ctDNA/ctRNA mutations in patient 
146-0013. The same TP53 mutation was observed at all three timepoints. CDKN2A 






Figure 32: Longitudinal allele frequency tracking of ctDNA/ctRNA mutations in patient 





Figure 33: Longitudinal allele frequency tracking of ctDNA/ctRNA mutations in patient 












Figure 34: Longitudinal allele frequency tracking of ctDNA/ctRNA mutations in patient 









I then manually analyzed the de-duplicated BAM files on IGV to search for the 
same mutations identified from primary tumors in the matched plasma samples. The de-
duplicated BAM files are BAM files removing those sequencing reads that might contain 
PCR or sequencing errors according to the molecular barcodes (Figure 35). Molecular 
barcodes could also be used to perform quantitative analysis to obtain copy of mutation 
per ml of plasma. 
In this manual analysis, I was able to detect somatic mutations in the plasma of 
additional three patients (three TP53 mutations). Figure 36 to Figure 38 demonstrated the 
result of manual analysis using IGV. In patient 146-0010 (Figure 36), a TP53 mutation 
(Chr17:7577120, C to T) was detected in two of four timepoints. In patient 146-0014 
(Figure 37), a TP53 mutation (Chr17:7579414, C to T) was detected only at timepoint 1. 
In patient 146-0055 (Figure 38), a TP53 mutation (Chr17:7577538, C to T) was detected 
in two of three timepoints. The average of DFS in those three patients is 10.8 months 
(4.6, 9.9, and 17.9 months; lead time: 3.23, 9.79, and 17.71 months). 
In total, I was able to detect 8 of 13 patients who relapsed (62% sensitivity). The 
average of DFS in those 8 patients is 7.2 months. The lead time of detection of the 






Figure 35: Concept of molecular barcode. Incorporation of molecular barcodes into each 
DNA molecule before PCR allows to eliminate PCR or sequencing errors during 






Figure 36: Manual analysis of sequencing reads containing mutation using IGV (146-
0010). In patient 146-0010, TP53 mutation was detected at timepoint 1 (P1) and 3 (P3). 
This mutation is at locus chr17:7673802, where the wild type allele is C, whereas the 
mutant allele is T. Total count represents the unique sequencing reads. 
  

















Figure 37: Manual analysis of sequencing reads containing mutation using IGV (146-
0014). In patient 146-0014, TP53 mutation was detected at timepoint 1 (P1). This 
mutation is at locus chr17:7676096, where the wild type allele is C, whereas the mutant 
allele is T. Total count represents the unique sequencing reads. 
  

















Figure 38: Manual analysis of sequencing reads containing mutation using IGV (146-
0055). In patient 146-0055, TP53 mutation was detected at timepoint 2 (P2) and 3 (P3). 
This mutation is at locus chr17:7674220, where the wild type allele is C, whereas the 
mutant allele is T. Total count represents the unique sequencing reads. 
  
P1 P2 P3 
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3.3.3 Comparison of ctDNA-only detection versus ctDNA/ctRNA co-detection for 
relapse prediction 
 
In chapter 2, I was able to detect somatic mutations in the plasma of four patients 
using ctDNA out of 13 who relapsed in the BRE09-146 trial. In this chapter, with 
incorporation of ctRNA into ctDNA sequencing assay, along with better chemistries of 
library preparation, I was able to increase the number of patients from four to eight with 
detectable mutations in the plasma. Those additional patients are: 146-0010, 146-0014, 
146-0055, and 146-0135. 
Another four patients (146-0005, 146-0013, 146-0102, and 146-0112) had 
detectable mutations using both two strategies. However, there are still some differences. 
In patient 146-0005, TP53 mutation was detected at two of three timepoints (P2 and P4) 
previously (Figure 16). Here I detected mutation at all four timepoints (Figure 30). In 
patient 146-0013, mutations were detected at two of four timepoints (P1 and P4 for both 
TP53 and CDKN2A mutations) (Figure 17). Here I detected mutations at all three 
timepoints for TP53; two of three timepoints for CDKN2A (P1 and P3) (Figure 31). In 
patient 146-0102, AKT1 mutation was detected at the only one timepoint (P1) (Figure 
18). Here I detected mutation at three of four timepoints except P1 (Figure 32). In patient 
146-0112, TP53 mutation was detected at the only one timepoint (P1) (Figure 19). Here I 
also detected mutation at the only one timepoint (P1) (Figure 34). See Table 5 for more 

























Table 5: Summary of sequencing result for early TNBC using ctDNA-only and 






































Detected in both methods













To trace the presence of cancer using circulating materials from patients or 
individuals with higher risk to relapse has become very popular in recent years. Although 
several studies showed that some tumor-specific proteins can be potential biomarkers to 
detect cancers, the technologies to study novel proteins that are related to cancer are 
limited. In addition, the sensitivity and specificity of detecting cancers using protein 
biomarkers are also lacking [93, 94]. With the advances of sequencing technologies on 
DNA and RNA during the past decade, the paradigm of studying biomarkers from 
circulation has shifted to detecting circulating tumor nucleic acids using NGS and ddPCR 
technologies, specifically ctDNA.   
In 2013, Dawson et al. showed that in metastatic breast cancer, ctDNA can confer 
the highest sensitivity among three most common circulating biomarkers (ctDNA, CTC, 
and CA 15-3) used in breast cancer detection [52]. In early detection, several studies [51, 
73, 82] showed that using ctDNA had limited sensitivity in early breast cancer. A study 
conducted by my group in 2017 also showed congruence of moderate sensitivity in early 
TNBC patients who were “disease-free” during the times that the plasma samples were 
collected [87]. I was able to detect somatic mutations from plasma samples in 4 out of 13 
relapsed patients. Details described in Chapter 2. 
In this chapter, I demonstrated the strategies to resolve biological and 
technological issues to enhance sensitivity of detection in early TNBC. To tackle the 
biological limitation of using ctDNA, I first utilized ddPCR technology to validate if 
adding ctRNA into ctDNA assay will have more mutant molecules detected. The result 
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showed that in the plasma of a metastatic cancer patient, there was a 47.9% and 83.9% 
increase in ctDNA/ctRNA group of detecting TP53 mutation and KRAS mutation, 
respectively. This result showed potential application of ctDNA/ctRNA co-detection to 
increase the sensitivity of predicting recurrence in early breast cancer. 
 To enhance the technical-based sensitivity, I utilized Roche’s Avenio ctDNA 
Analysis system, which is hybrid capture based methodology in addition to applying 
molecular barcode technology. As described previously, including molecular barcodes in 
library preparation will reduce the false positive rate by eliminating PCR and sequencing 
errors. Moreover, quantitative analysis can be complemented by having molecular 
barcode incorporated into the ends of targeted DNA molecules during the adaptor ligation 
step prior to any PCR reactions. 
 I first examined the feasibility of incorporating ctRNA into the Avenio ctDNA 
analysis system. In the plasma samples of six metastatic breast cancer patients, I 
identified the numbers of mutant molecules in the ctDNA/ctRNA co-detection group 
were all higher than the corresponding mutations in ctDNA-only group. The average 
percentage increase was 67% (range=2.8%-385%). The allele frequencies of those 
mutations were similar in both groups, as well as in the reports of Foundation Medicine, 
suggesting that similar to cfDNA, a significant amount of cfRNA was from normal tissue 
as well. 
 I then performed the same experiment on plasma samples from BRE09-146, but 
only for the ctDNA/ctRNA co-detection portion. I was able to detect the same mutations 
in those four patients with detectable ctDNA in Chapter 2 (see Table 5). In patient 146-
0005, and patient 146-0013, detecting ctDNA/ctRNA showed better sensitivity: in each 
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mutation, at least one timepoint showed negative previously but positive in new method. 
On the contrary, in patient 146-0102, P1 showed positive previously but negative in new 
method. In patient 146-0112, it showed similar level of allele frequency in both methods. 
 Besides the four concordant patients, the reports showed one additional patient 
(146-0135) called by the standard analysis pipeline of Avenio ctDNA Analysis Server. 
This patient had two of four timepoints with the same TP53 mutation. Further, the 
manual analysis searching for the known somatic mutations revealed three additional 
patients with detectable mutations. Those four patients had 4.6, 6.4, 9.9, and 17.9 months 
of DFS individually. 
To summarize this chapter, I found that by leveraging ctDNA/ctRNA co-detection 
(improving the biological-based sensitivity), along with better NGS technology 
(improving the technical-based sensitivity), I was able to detect somatic mutations in 
plasma samples from 8 out of 13 patients who had a recurrence in early TNBC. The 
sensitivity of MRD detection was improved from 31% to 62%. The average DFS was 
increased from 4.6 months to 7.2 months. The most distant recurrence detected was 17.9 
months. The lead time of detection of the mutation in the plasma to clinical recurrence 
ranged from 0.07 to 17.71 months (average: 6.71 months). Since I only processed plasma 
samples from patients who had a recurrence so far, only sensitivity is available. The rest 
of the plasma samples from patients who had no recurrence will need to be processed in 




Chapter 4: Summary 
 
In the recent years, studies indicated that some of the TNBC patients may benefit 
from one of two FDA-approved treatments other than chemotherapy: (1) PARP inhibitor 
Talazoparib for patients with advanced or metastatic HER2-negative breast cancer and 
germline BRCA1/2 mutations [12, 13]; (2) immunotherapeutic agent Atezolizumab for 
unresectable locally advanced or metastatic TNBC patients with PD-L1 positive tumors 
[14]. Although there have been advances in therapies for TNBC, the current standard of 
care for the majority of TNBC patients, in early and advanced-stages, is still 
chemotherapy. A significant proportion of patients with early-stage TNBC are treated 
with neoadjuvant chemotherapy. A stark dichotomy exists in outcome based on response 
to neoadjuvant therapy. Approximately a third of patients will achieve a pCR and will 
have a favorable overall survival outcome. In contradistinction, two-thirds of patients will 
have RD after neoadjuvant chemotherapy and are at a high risk of relapse. For the TNBC 
patients with RD, detecting the presence of MRD earlier is critical to be able to intervene 
and perhaps increase the survival. 
 Precision medicine has become widely accepted lately, especially in oncology, for 
the diagnosis, treatment selection, and therapy observation by utilizing patient’s 
molecular profiling. Tissue biopsies are the standard for cancer diagnosis for molecular 
profiling to guide the selection of therapy. However, there are drawbacks of using tissue 
biopsies. For example, one single biopsy cannot completely represent the heterogeneity 
of the whole tumor or metastases. In addition, some lesions are not safe or feasible to 
access. Another important tool of precision medicine is liquid biopsies, an emerging 
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method for minimally-invasive cancer detection by analyzing the tumor-derived material 
from bodily fluids, mainly blood. Liquid biopsies have the advantages in clinical 
application for several reasons: (1) they are considered non- or minimal-invasive; (2) 
serial sampling allows clinicians to observe the real-time status of patient instead of one 
snapshot; (3) compared to standard diagnosis tools, such as imaging which has strict 
regulations for the frequency. Liquid biopsies can be performed repeatedly over the 
course of therapy.  
Blood-based cancer biomarkers can be defined as any biological materials 
released by tumor tissues. Previously, protein biomarkers were widely used in cancer 
diagnostics within liquid biopsies. There are two protein biomarkers approved by FDA 
which are more relevant to breast cancer: carcinoembryonic antigen (CEA) and MUC-1 
(including MCA, BRMA CA549, CA27.29, and CA 15-3) [94]. However, the major 
disadvantages of these two protein biomarkers are lack of sensitivity and specificity [93]. 
In 2013, Dawson et al. compared three blood-based biomarkers in metastatic patients: CA 
15-3, CTCs, and ctDNA. The result indicated that ctDNA has the highest sensitivity 
among those three biomarkers [52]. The origin of ctDNA is from tumor tissues or CTCs. 
Because ctDNA carries tumor-specific aberrations, it is considered to be a more favorable 
biomarker over a protein biomarker. Although ctDNA usually comprises very small 
portion of total cfDNA in early-stage cancer patients, with the advances of molecular 
technologies I are able to detect the low amount of ctDNA out of total cfDNA. 
In this dissertation, I first showed that by detecting ctDNA, I was able to predict 
rapid recurrence, but not late recurrence in early TNBC after neoadjuvant chemotherapy. 
The sensitivity of detection was moderate and with high specificity.  
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To tackle the biological-based issue I incorporated ctRNA into ctDNA detection. 
Unlike ctDNA, ctRNA can be actively secreted from living tumor cells within exosomes. 
I expected to see an increase in mutant molecules detected after adding ctRNA into 
ctDNA. My preliminary data of ddPCR applied on a single metastatic cancer patient 
supported my hypothesis. The ddPCR technology is considered to have a higher 
sensitivity compared to NGS technology. However, ddPCR can usually only screen one 
variant at a time. Moreover, in my study, several mutations were located at the edge of 
exonic regions, making it impossible to design an assay for both ctDNA and ctRNA 
detection simultaneously. Therefore, NGS technology is still the best fit in this study for 
multiple-mutation detection and ctDNA/ctRNA co-detection.  
I also worked on finding a better solution to enhance the technical-based 
sensitivity. In chapter 2, I utilized amplicon-based technology to detect ctDNA. In the 
analysis, I found that there were significant amounts of false positive calls by comparing 
the results to corresponding tumor sequencing data. In chapter 3, I utilized the Roche 
Avenio ctDNA analysis system, which applies hybrid capture enrichment along with 
molecular barcode technology to eliminate false positive signals. It is also considered to 
detect ctDNA down to 0.1% allele frequency. Although the Roche Avenio ctDNA 
analysis kit was designed for ctDNA detection only, I successfully merged ctRNA 
detection into the existing system by conducting the proof of concept experiment on 
plasma samples from six metastatic breast cancer patients. The results showed that 
comparing to ctDNA-only, ctDNA/ctRNA co-detection can increase the detectable 
mutant molecules from 2.8% to 385%. By improving biological-based and technical-
based sensitivity, I was able to enhance the sensitivity of detection from 31% to 62% in 
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early TNBC patients who were considered disease-free during plasma collections. I 
increased the range maximum of lead time from 8.87 to 17.71 months. The specificity of 
new strategy will be confirmed by the following experiments in the future. For patients 
who had a recurrence but did not have detectable mutant molecules from their plasma 
samples, most had a late recurrence (DFS range: 22.17 to 33.74 months) except for two 
patients who had a rapid recurrence (2.66 and 3.12 months DFS). The possible 
explanation for these two patients without detectable mutation could be due to the rapid 
progression in a very short time of their plasma collection. This dissertation also presents 
a significant look at detecting ctDNA-only (amplicon-based) versus ctDNA/ctRNA 
(hybrid capture) as the samples collected from patients were split into two aliquots to 
allow for comparison. 
Other studies [51, 82] showed serial sampling can increase the detection of 
sensitivity over time. However, my samples were from a retrospective study, which had 
plasma samples collected in the four months after neoadjuvant chemotherapy and 
surgery. This made serial sampling impossible under current setting. Although there are 
limitations based on this timeline of samples, my purpose was to detect the MRD in the 
very early stage of TNBC to predict who will relapse. Another limitation of my study was 
the amount of plasma as most of my samples only had one milliliter available.  
  In summation, this dissertation provides the first observation for co-detection of 
ctDNA and ctRNA in the setting of early TNBC patients who were considered “disease-
free” after neoadjuvant chemotherapy. I successfully enhanced the sensitivity of detection 
from 31% to 62%. With this work, I hope that it can provide early TNBC patients to have 
better opportunities for more timely therapeutic intervention and eventually improve the 
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overall survival. The future directions for further improving the detection of MRD can be 
focused on two parts: (1) increasing the amount of plasma collection; (2) incorporating 
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